Table 2 Localization of macrovascular tumour invasion (n = 124) and changes during follow-up (n = 83) according to therapeutic anticoagulation
Patient characteristics | Study cohort, n = 124 (100%) | Anticoagulation, n = 24 (19%) | No anticoagulation, n = 100 (81%) | p-value |
Localization and degree of occlusion, n (%) | ||||
 Main portal vein involved | 47 (38%) | 14 (58%) | 33 (33%) | 0.022 |
  Total | 19 (15%) | 6 (25%) | 13 (13%) | 0.069 |
  Partial | 28 (23%) | 8 (33%) | 20 (20%) | |
 Left and/or right portal branch | 53 (43%) | 8 (33%) | 45 (45%) | 0.299 |
  Total | 25 (20%) | 2 (8%) | 23 (23%) | 0.272 |
  Partial | 28 (23%) | 6 (25%) | 22 (22%) | |
 Left and/or right portal branch and other veins (hepatic veins, splenic vein, VCI, SMV) | 17 (14%) | 2 (8%) | 15 (15%) | 0.522 |
  Total | 7 (6%) | 2 (8%) | 5 (5%) | 0.237 |
  Partial | 10 (8%) | – | 10 (10%) | |
 Other veins (hepatic veins, splenic vein, VCI, SMV) | 7 (6%) | – | 7 (7%) | 0.344 |
  Total | 7 (6%) | – | 7 (7%) | |
  Apposition thrombus | 49 (40%) | 12 (50%) | 37 (37%) | 0.242 |
  Venous congestion | 22 (18%) | 5 (21%) | 17 (17%) | 0.766 |
Best radiological response of macrovascular tumour invasion at 3–6 months, n (%) | All patients with available FU imaging, n = 83 (100%) | Anticoagulation, n = 17 (20%) | No anticoagulation, n = 66 (80%) | p-value |
 Regression | 14 (17%) | 3 (18%) | 11 (17%) | 0.951 |
 Stabilization | 32 (39%) | 7 (41%) | 25 (38%) | |
 Progression | 37 (45%) | 7 (41%) | 30 (45%) | |